COVID-19 is not linked to worsening inflammatory bowel disease outcomes

COVID-19 is not linked to worsening inflammatory bowel disease outcomes

COVID-19 did not have a long-term impact on the course of inflammatory bowel disease (IBD), according to a study published online November 4 in Therapeutic advances in gastroenterology.

Simon J. Hong, MD, of NYU Langone Health in New York, and colleagues assessed the effect of COVID-19 on long-term IBD outcomes. The analysis included 251 cases (45% ulcerative colitis; 55% Crohn’s disease) and 251 controls, with a median follow-up of 394 days.

Researchers found that the primary composite outcome of IBD-related hospitalization or surgery occurred in 29 cases (12%) versus 38 controls (15%). COVID-19 was not associated with an increased risk of adverse IBD outcomes (adjusted relative risk, 0.84; 95% confidence interval, 0.44 to 1.42). There were also no significant differences observed in adverse IBD outcomes based on COVID-19 severity (adjusted hazard ratios [95 percent confidence intervals]2.43 [1.00 to 5.86] and 0.68 [0.38 to 1.23] for severe COVID-19 and mild to moderate COVID-19, respectively).

“In this multicenter study, COVID-19 did not alter the long-term course of IBD; however, severe COVID-19 may portend a worse course and prognosis of IBD disease,” the authors write. “Risk mitigation and vaccination remain important strategies in the management of patients with IBD during the ongoing COVID-19 pandemic.”

Several authors disclosed financial ties to the pharmaceutical industry.

More information:
Summary/Full text

Copyright © 2022 Health Day. All rights reserved.

Quote: COVID-19 not linked to worsening inflammatory bowel disease outcomes (2022, Nov 18) Retrieved Nov 18, 2022 from -bowel-disease.html

This document is subject to copyright. Except for fair use for purposes of private study or research, no part may be reproduced without written permission. The content is provided for information only.

Leave a Comment

Your email address will not be published.